Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Ovarian Neoplasms 6Carcinoma, Non-Small-Cell Lung 4Fallopian Tube Neoplasms 3Carcinoma, Ovarian Epithelial 3Breast Neoplasms 3Non Small Cell Lung Carcinoma NSCLC 2NSCLC 2Melanoma 2Triple Negative Breast Neoplasms 1Recurrence 1Primary Breast Cancer 1Non-Small Cell Lung Cancer With HER2- Mutations 1Neoplasm Metastasis 1Lung Neoplasms 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Carcinoma 1

Interventions

Pemetrexed 2Gemcitabine 2Cisplatin 2Carboplatin 2CP protocol 2durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Non Small Cell Lung Carcinoma NSCLC × CP protocol × Clear all
NCT02542293 2026-05-01

NEPTUNE

AstraZeneca

Phase 3 Active not recruiting
953 enrolled 29 charts
Thoracic

Non Small Cell Lung Carcinoma NSCLC

NCT03003962 2026-03-11

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

AstraZeneca

Phase 3 Active not recruiting
669 enrolled 54 charts
Thoracic

Non Small Cell Lung Carcinoma NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡